We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
- Authors
Boye, J; Elter, T; Engert, A
- Abstract
The chimeric anti-CD20 monoclonal antibody rituximab has become part of the standard therapy for patients with non-Hodgkin's lymphoma (NHL). To date, more than 300 000 patients have been treated with rituximab worldwide, including patients with indolent and aggressive NHL, Hodgkin's disease and other B-cell malignancies. Combination of rituximab with cytotoxic agents or cytokines has been explored in a number of different studies. Rituximab is now also approved for patients with diffuse large B-cell lymphoma when combined with standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone). The monoclonal antibody is generally well tolerated. Most adverse events are infusion-associated, including chills, fever and rigor related to the release of cytokines.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Vol 14, Issue 4, p520
- ISSN
0923-7534
- Publication type
Journal Article
- DOI
10.1093/annonc/mdg175